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Objective: The association of elevated serum C-reactive protein (CRP) with lower uri-
nary tract symptoms (LUTS) suggests a possible role of inflammation. We investigated 
whether measurement of urine CRP levels can complement the deficit in the specifi-
city of serum CRP levels as potential biomarkers of lower urinary tract inflammation.
Patients and Methods: Serum CRP levels were measured in 97 patients with LUTS; 
urinary CRP was additionally measured in 20 of the patients. Bladder expression of 
CRP was quantified by real-time polymerase chain reaction on human bladder t issue 
obtained from 15 organ donors.
Results: Significantly higher serum CRP levels were noted in overactive bladder 
(OAB) wet (n = 18; 2.96 ± 0.47 mg/L), chronic prostatitis (n = 5; 3.00 ± 1.05 mg/L), 
benign prostatic hyperplasia (n = 20; 1.13 ± 0.17 mg/L), and acute febrile bacterial 
infection (n = 5; 97.71 ± 36.28 mg/L) compared to in asymptomatic controls (n = 20; 
0.93 ± 0.27 mg/L). Serum CRP level was higher in OAB wet than in OAB dry (n = 20). 
Urinary CRP level was higher than 0.15 mg/L in only one man with bacterial prostatitis 
and sepsis. The mRNA expression of CRP was very modest and several fold lower 
than the expression of housekeeping genes in the detrusor or urothelium.
Conclusion: Serum CRP was elevated with different disease entities in patients with 
LUTS. The synthesis of CRP is unlikely in the bladder and the protein is not a normal 
urine constituent. This pilot study has led us to infer that urinary CRP is unlikely to 
serve as a biomarker of LUTS. Sensitive but nonspecific elevation of serum CRP level 
suggests an inflammatory mechanism with LUTS.
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1.  Introduction
The causes of lower urinary tract symptoms (LUTS) can 
be traced to a number of pathologic conditions, including 
benign prostatic hyperplasia (BPH), overactive bladder 
(OAB), interstitial cystitis (IC), chronic prostatitis, and 
urinary tract infection. No matter what the cause, in-
flammation has been linked to the development of 
LUTS.1,2 Inflammation is often present in prostate biopsy 
specimens; this has led to the hypothesized association 
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of chronic inflammation with BPH.3 Abnormal sensory 
function of the prostate plays an imp ortant role in the 
symptoms of chronic prostatitis or protatodynia.4
Urine, which is easy to collect, is an ideal biologic sam-
ple for the discovery of noninvasive biomarkers of human 
diseases. Previous studies have suggested the association 
of inflammation with OAB symptoms by the significant el-
evation of nerve growth factor (NGF) and prostaglandin 
E2 (PGE2) levels in the urine of OAB patients.5 In addition, 
IC patients have also been reported to have elevated NGF 
levels in bladder tissue.6 Objective measurement of these 
inflammatory markers in the urine highlight the associa-
tion of LUTS with lower urinary tract inflammation.
One widely studied general marker of inflammation 
and infection is C-reactive protein (CRP). Its serum levels 
have been reported to rise dramatically during inflam-
matory processes occurring in the body. Higher than 
normal serum CRP levels are well accepted as a proxy 
for heart disease risk,7 and serum CRP level is used to 
determine disease progression or treatment effectiveness. 
However, unlike other inflammatory biomarkers detected 
in human and animal urine, CRP levels in the bladder tis-
sue and urine of LUTS patients has not been previously 
reported.5,8,9 Therefore, this study was undertaken to 
examine CRP expression in bladder tissue, and serum 
and urine levels of CRP in patients with LUTS.
2.  Materials and Methods
2.1.  Collection of urine and serum
A total of 97 patients with a mean age of 60.7 ± 2.0 years 
were enrolled in the study after they gave informed con-
sent; 77 patients had LUTS (frequency, urgency with or 
without incontinence, nocturia, and voiding symptoms) 
and 20 did not (they served as the control group). After 
physical examination and record review, clinical charac-
teristics were documented. Nine patients had IC, five 
had chronic prostatitis, 38 had OAB (OAB wet—with 
at least one episode of urgency incontinence daily, 
n = 18; OAB dry—without urgency incontinence, n = 20), 
20 had BPH, and five had acute febrile bacterial infec-
tion related to the urinary tract. We did not have com-
plete prostate fluid study in the patients with chronic 
prostatitis.
Serum was collected from all 97 patients, and urine 
was additionally collected from the 20 control patients 
(Table 1). Serum and urine samples were obtained dur-
ing a single clinic visit. Collected urine samples were 
immediately placed on ice in the clinic. Samples were 
centrifuged at 2400g for 10 minutes. The supernatant 
was separated into 1.5 mL aliquots and preserved in a 
−80°C freezer.
Table 1 Characteristics of patients with lower urinary tract symptoms and serum C-reactive protein levels*
Disease/serum Control OAB dry OAB wet IC/PBS CP/CPPS BPH Acute febrile bacterial 
CRP (mg/L) (n = 20) (n = 20) (n = 18) (n = 9) (n = 5) (n = 20) infection (n = 5)
 0.56 0.15 1.72 0.15  2.76 3.20 177.00
 0.18 0.69 3.70 1.57 13.50 0.62 190.00
 0.31 0.26 4.16 5.01  1.08 1.32  38.40
 0.34 0.46 4.30 1.12  1.83 0.77  70.80
 1.33 0.84 1.27 0.52  2.12 0.82  12.33
 0.00 0.61 1.55 0.52  0.16 
 0.59 1.16 5.00 9.84  0.18 
 0.97 0.71 1.70 0.96  0.55 
 0.30 0.71 0.27 1.05  2.00 
 0.42 2.05 7.30   0.50 
 2.64 0.64 6.50   1.01 
 0.72 1.10 2.34   1.34 
 0.19 0.33 4.51   2.12 
 4.24 0.93 2.26   0.40 
 3.71 2.07 2.55   1.58 
 0.60 1.38 1.46   1.56 
 0.35 1.18 1.95   1.83 
 0.49 3.02 0.67   0.57 
 0.29 0.87    1.35 
 0.35 2.00    0.62 
Mean ± SE 0.93 ± 0.27 1.06 ± 0.16 2.96 ± 0.47 2.30 ± 1.06 4.26 ± 2.33 1.13 ± 0.17 97.71 ± 36.28
p compared  0.064 0.0002 0.0854 0.0109 0.0515 0.0008
 with control 
*One way ANOVA with Kruskal-Wallis and Dunn’s post hoc test: control vs. OAB wet, p < 0.001; control vs. acute febrile UTI, p < 0.001; OAB dry 
vs. OAB wet, p < 0.05; OAB dry vs. acute febrile UTI, p < 0.01; BPH vs. acute febrile UTI, p < 0.01. CRP = C-reactive protein; OAB = overactive 
bladder; IC = interstitial cystitis; PBS = painful bladder syndrome; CP = chronic prostatitis; CPPS = chronic pelvic pain syndrome; BPH = benign 
prostatic hyperplasia; SE = standard error; UTI = urinary tract infection.
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2.2.  High-sensitivity CRP assay
Measurement of CRP level in venous blood samples and 
urine samples was done by the hospital’s clinical pathol-
ogy laboratory using a standard assay.
2.3.  Real-time polymerase chain reaction
assay for CRP
Real-time polymerase chain reaction (PCR) was done to 
quantify CRP expression in human bladder tissue sam-
ples obtained from 15 organ donors with unknown dis-
ease status. Separated tissue pieces of human detrusor 
(7) and urothelium (8) were stored in RNAlater (Ambion 
Inc., Austin, TX, USA) at 4°C until RNA isolation. RNA sam-
ples were isolated from bladder tissues using RNeasy kits 
(QIAGEN Inc., Valencia, CA, USA) according to the manufac-
turer’s protocol. RNA was quantified by a spectropho-
tometer (Eppendorf AG, Hamburg, Germany). Real-time 
quantitative PCR reactions were performed according to 
the manufacturer’s (SABiosciences, A QIAGEN Company, 
Frederick, MD, USA) protocol. Briefly, cDNA was prepared 
from 1 μg total RNA using an RT2 PCR array first strand 
kit (SABiosciences, A QIAGEN Company).
Quantitative PCR reactions were done in a 25 μL 
mixture, which included 12.5 μL RT2 real-time SYBR 
green/ROX PCR master mix (SABiosciences), 10.5 μL nu-
clease-free H2O, 1 μL specific human primers, including 
10 μM each of CRP (SABiosciences) and beta-actin 
(forward: 5 GATGCGTTGTTACAGGAAG 3; reverse: 5 
CATTACATAATTTACACGAAAGC 3), and 1 μL template 
cDNA. Quantitative PCR amplification was done with an 
initial 10-minute step at 95°C, followed by 40 cycles at 
95°C for 30 seconds, 55°C for 1 minute and 72°C for 30 sec-
onds, followed by dissociation curve analysis. Real-time 
quantitation was performed using the Mx3000P QPCR 
System (Stratagene Corp., Santa Clara, CA, USA) with 
fluorescence threshold values calculated using Mx3000P 
System software.
2.4.  Statistical analysis
Data were analyzed using GraphPad Prism version 4.0 
(GraphPad Software Inc., La Jolla, CA, USA). Descriptive 
statistics were denoted as mean ± standard error. Kruskal-
Wallis with Dunn’s post hoc test was used for continuous 
measures of non-normally distributed data. A p value less 
than 0.05 was considered to be statistically significant.
3.  Results
Serum CRP levels were found to vary in patients with 
LUTS (Table 1). CRP levels were categorized into two 
groups: ≤ 1 mg/L and > 1 mg/L. Four of the 20 control pa-
tients (20%), 8 of the 20 OAB dry patients (40%), 10 of 
the 20 BPH patients (50%), 5 of the 9 IC patients (55.6%), 
5 of the 5 chronic prostatitis patients (100%), 16 of the 
18 OAB wet patients (88.9%), and 5 of the 5 patients 
with acute febrile bacterial infection (100%) had CRP 
level > 1 mg/L. These results indicate that different d isease 
entities of LUTS may have different proportions of pa-
tients with inflammation; among them, the highest pro-
portion was noted in the OAB wet group (Figure 1).
OAB wet, chronic prostatitis, BPH, and acute febrile bac-
terial infection groups had significantly higher serum CRP 
levels than control (2.96 ± 0.47, 4.26 ± 2.33, 1.13 ± 0.17 and 
97.71 ± 36.28 mg/L, respectively, versus 0.93 ± 0.27 mg/L; 
p = 0.0002, 0.0109, 0.0515 and 0.0008, respectively). Fur-
thermore, OAB wet (2.96 ± 0.47 mg/L) patients had higher 
serum CRP levels than OAB dry patients (1.06 ± 0.16 mg/L). 
Patients with acute febrile bacterial infection had higher 
serum CRP levels than patients with OAB dry and BPH. 
These results indicate that different disease entities of 
LUTS may have different degrees of inflammation.
Urinary CRP level was below 0.15 mg/L except for one 
man with bacterial prostatitis and sepsis, who had a uri-
nary CRP level of 0.86 mg/L. The mRNA expression of CRP 
was very modest and several fold lower than the expres-
sion of housekeeping genes in the detrusor or urothe-
lium (data not shown). These results indicate that CRP 
synthesis is unlikely in the bladder and the protein is 
unlikely to be a normal urine constituent.
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Figure 1 Graphical distribution of serum C-reactive protein 
(CRP) levels in different disease categories of lower urinary tract 
symptoms demonstrates the variance in inflammation with dif-
ferent disease entities. The levels of serum CRP in acute febrile 
bacterial infection (97.71 ± 36.28 mg/L, n = 5) were 10-fold higher 
than in the other groups. The mean levels of serum CRP in over-
active bladder (OAB) wet (2.96 ± 0.47 mg/L) and benign prostatic 
hyperplasia (BPH; 1.13 ± 0.17 mg/L) were significantly higher 
than in asymptomatic controls (0.93 ± 0.27 mg/L). OAB wet 
patients also had higher serum CRP levels than OAB dry patients 
(one way ANOVA with Kruskal-Wallis and Dunn’s post hoc test). 
Note the logarithmic scale on the y axis. IC = interstitial cystitis; 
PBS = painful bladder syndrome.
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4.  Discussion
This study showed that serum CRP was elevated to vari-
ous degrees in patients with LUTS. OAB wet patients had 
higher serum CRP than normal control and OAB dry pa-
tients. In patients with acute febrile infection, CRP levels 
were extraordinarily high. Serum CRP level in patients 
with LUTS may not specifically reflect the condition of 
the lower urinary tract, as its levels are more likely to be 
influenced by the systemic inflammatory condition. Our 
pilot study suggests that urinary CRP is unlikely to serve 
as a biomarker of local bladder inflammation.
LUTS comprises various lower urinary tract conditions 
and can also be attributed to systemic factors. The eval-
uation of LUTS is largely dependent on different kinds of 
symptom scores and questionnaires.10 However, objec-
tive parameters that can detect disease status and mon-
itor disease progression or therapeutic effects are lacking. 
Recent studies from bladder or prostate biopsies have 
suggested that OAB, IC and BPH are related to tissue in-
flammation.3,5,11 Investigation of inflammation-associated 
proteins in the bio-fluid of these patients is of widespread 
interest. Kupelian et al.1 demonstrated a dose-response 
relationship between increased CRP levels and increased 
odds ratio of LUTS in both men and women, which sup-
ports the hypothesized role of inflammatory processes 
in the etiology of LUTS.
Our current results of elevated CRP levels in different 
LUTS conditions also support the concept of inflamma-
tion related to LUTS and gives credence to serum CRP 
levels as a potential surrogate marker of LUTS. In an ef-
fort to improve the specificity of markers, various stud-
ies have looked at the serum derivative, urine, to try to 
find disease-specific markers of the functional status of 
different organs, including the urinary tract.12 It is logical 
to expect superior reflection of bladder biochemistry in 
urine compared to serum.13 Kim et al.5 reported that uri-
nary NGF and PGE2 levels were elevated in OAB patients 
compared to controls. A study conducted by Liu and Kuo14 
showed that urine NGF levels were very low in normal 
controls, while patients with OAB had significantly higher 
urinary NGF levels. Furthermore, OAB wet patients had 
significantly higher urinary NGF levels than OAB dry pa-
tients, which concurs with our observation of higher 
serum CRP levels in OAB wet than OAB dry patients. 
Taken together, it may be argued that OAB wet is associ-
ated with a more severe degree of inflammation than 
OAB dry. Recently reported urinary chemokines profile 
in OAB patients also corroborates this inference of se-
vere inflammation in such patients.15
CRP is produced and secreted by the liver in re-
sponse to inflammatory processes occurring in the body. 
The current study showed that urinary CRP was rarely 
detected and the mRNA expression of CRP was very 
modest and several fold lower than the expression of 
housekeeping genes of beta-actin in the detrusor or urothe-
lium. These observations led us to infer that urinary CRP 
levels are much lower than serum CRP levels, and the 
current available methods for detecting CRP might not 
be sensitive enough to develop a urinary assay. Therefore, 
urinary CRP cannot complement the deficit in the specifi-
city of serum CRP level as a potential biomarker of local 
inflammation in the urinary tract.
The current study showed that the proportion of pa-
tients with LUTS and elevated CRP level (> 1 mg/L) was 
higher than in controls and lower than in patients with 
acute febrile infection. Therefore, in assessing CRP ele-
vation, the presence of other inflammatory disease and 
infection should be considered because CRP is a nonspe-
cific inflammatory marker. However, assays for serum 
CRP are widely available and simple. Therefore, serum 
CRP might be useful as a surrogate marker for monitor-
ing disease conditions and response to therapeutic in-
terventions in patients with LUTS. Serum CRP may also 
be useful in conjunction with urinary inflammatory chem-
okines as a multivariant biomarker of LUTS.15 We sug-
gest that checking serum CRP in patients who do not 
respond to conventional therapy for OAB or LUTS might 
guide specific anti-inflammatory treatment for those 
with elevated serum CRP.
Our study suggests that urinary CRP is unlikely to serve 
as a biomarker of local bladder inflammation. Serum 
CRP is elevated with different disease entities in patients 
with LUTS. Sensitive but nonspecific elevation of serum 
CRP suggests an inflammatory mechanism with LUTS.
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